Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 3A

CHEMBL1899 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:14:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1899
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 3A as ChEMBL target CHEMBL1899, mapped to UniProt P46098. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 3A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1899
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P46098
5-hydroxytryptamine receptor 3A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 3A matters

As of 2026-09-14

5-hydroxytryptamine receptor 3A is reviewed as 5-hydroxytryptamine receptor 3A (UniProt P46098); 5-hydroxytryptamine receptor 3A shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 7 linked drugs keep this evidence frame grounded.; the current evidence base includes 22 approved drugs, 3328 compounds, and 509 assays, with lead potency reaching pChEMBL 10.5.

Disease context
cancer

5-hydroxytryptamine receptor 3A shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 7 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DOLASETRON MESYLATE, GRANISETRON, GRANISETRON HYDROCHLORIDE.

Start review with cancer because it currently carries approved-linked support. Linked drugs include DOLASETRON MESYLATE, GRANISETRON, GRANISETRON HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 7 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 22 approved drugs, 3328 compounds, and 509 assays for this target. The dominant activity type is KI. CHEMBL1189679 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL1189679 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
22 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 3A matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P46098, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3328
Total Compounds
509
Total Assays
22
Approved Drugs
IC50: 814.0, KI: 879.0, EC50: 45.0, KD: 22.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1189679
 10.5 Ki Approved
No preferred name
CHEMBL261010
 10.4 Ki —
No preferred name
CHEMBL475331
 10.3 Ki —
No preferred name
CHEMBL1643895
 10.2 Ki Approved
No preferred name
CHEMBL46
 10.1 IC50 Approved

Approved Drugs

Structure Compound First Approval
RAMOSETRON
CHEMBL1643895
 2015
VORTIOXETINE
CHEMBL2104993
 2013
PALONOSETRON
CHEMBL1189679
 2003
ARIPIPRAZOLE
CHEMBL1112
 2002
ALOSETRON
CHEMBL1110
 2000
KETOTIFEN FUMARATE
CHEMBL1633
 1999
OLANZAPINE
CHEMBL715
 1996
GRANISETRON
CHEMBL289469
 1993
SUMATRIPTAN
CHEMBL128
 1992
ONDANSETRON
CHEMBL46
 1991
CLOZAPINE
CHEMBL42
 1989
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:14:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1899